| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.10.23 | Pixium Vision - Safeguard proceedings underway | 1.719 | Edison Investment Research | Pixium Vision announced that safeguard proceedings have been opened by the Commercial Court of Paris. Despite the company's best efforts in seeking financing options to extend its funding runway, it... ► Artikel lesen | |
| 10.10.23 | IRLAB Therapeutics - Collaboration to support FDA Ph III progression | 337 | Edison Investment Research | IRLAB is collaborating with two US-based advisory groups, Clintrex (clinical research company) and ProPharma Group (research consulting organisation) for expert guidance in preparing a brief package... ► Artikel lesen | |
| 10.10.23 | Helios Underwriting - Interim results deliver long-awaited upswing | 270 | Edison Investment Research | Helios Underwriting reported H123 EPS of 5.7p, a meaningful turnaround from a 4.4p loss in H122 and a 4.9p loss in FY22. It benefited from a much-improved combined ratio of 88% (H122: 95%) and a turnaround... ► Artikel lesen | |
| 10.10.23 | Channel Islands Property Fund - Channel Islanders working from the office | 188 | Edison Investment Research | Channel Islands Property Fund (CIPF) recorded a 5% y-o-y increase in rental income in H123 (to end March 2023) as the fund continues to see 100% rent collection and reduced its vacancy rate to just... ► Artikel lesen | |
| 10.10.23 | Lowland Investment Company - Dividend growth and NAV outperformance | 245 | Edison Investment Research | Since we published our detailed review of Lowland Investment Company (LWI) in August, quarterly DPS has been increased 4.9% to 1.6p, continuing a long track record of progressive dividends, and maintaining... ► Artikel lesen | |
| 10.10.23 | Immix Biopharma - A step toward delivering a practical CAR-T option | 367 | Edison Investment Research | Immix has announced encouraging updated clinical data for NXC-201, a B cell maturation antigen (BCMA) targeting CAR-T therapy, which is being developed by majority-owned subsidiary Nexcella, in both... ► Artikel lesen | |
| 10.10.23 | Ultimovacs - UV1 ODD a sign of positive things to come | 389 | Edison Investment Research | Ultimovacs has announced that the US FDA has granted orphan drug designation (ODD) to its cancer vaccine, UV1, for the treatment of mesothelioma. This is a positive development as the orphan designation... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 345 |
| EVOTEC | 314 |
| TUI | 228 |
| NVIDIA | 191 |
| DEUTSCHE BANK | 183 |
| BAYER | 170 |
| PLUG POWER | 153 |
| NEL | 141 |
| RHEINMETALL | 139 |
| SIEMENS ENERGY | 123 |
| COMMERZBANK | 113 |
| BARRICK GOLD | 112 |
| BASF | 110 |
| TESLA | 109 |
| VOLKSWAGEN | 100 |
| RWE | 99 |
| BYD | 95 |
| DEUTSCHE LUFTHANSA | 92 |
| ALLIANZ | 90 |
| DEUTSCHE TELEKOM | 87 |
| MERCEDES-BENZ | 86 |
| RENK GROUP | 84 |
| E.ON | 80 |
| HEIDELBERGER DRUCK | 79 |
| AIXTRON SE | 76 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
